MA49809A1 - Composés utilisés comme inhibiteurs de kinase - Google Patents

Composés utilisés comme inhibiteurs de kinase

Info

Publication number
MA49809A1
MA49809A1 MA49809A MA49809A MA49809A1 MA 49809 A1 MA49809 A1 MA 49809A1 MA 49809 A MA49809 A MA 49809A MA 49809 A MA49809 A MA 49809A MA 49809 A1 MA49809 A1 MA 49809A1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
compounds used
tyrosine kinase
compounds
inhibitors
Prior art date
Application number
MA49809A
Other languages
English (en)
French (fr)
Inventor
Nicolas Guisot
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MA49809A1 publication Critical patent/MA49809A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA49809A 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase MA49809A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors
PCT/GB2016/053968 WO2017103611A1 (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
MA49809A1 true MA49809A1 (fr) 2021-08-31

Family

ID=57590725

Family Applications (2)

Application Number Title Priority Date Filing Date
MA49809A MA49809A1 (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase
MA055064A MA55064A (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA055064A MA55064A (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase

Country Status (38)

Country Link
US (8) US10695323B2 (https=)
EP (2) EP3782994B1 (https=)
JP (3) JP6731483B2 (https=)
KR (2) KR102215792B1 (https=)
CN (9) CN114591242B (https=)
AU (4) AU2016373530B2 (https=)
CA (1) CA3008488C (https=)
CL (1) CL2018001591A1 (https=)
CO (1) CO2018006164A2 (https=)
CR (1) CR20180367A (https=)
CY (2) CY1123561T1 (https=)
DK (1) DK3390395T3 (https=)
EA (1) EA035132B1 (https=)
ES (2) ES2828431T3 (https=)
FI (1) FIC20240004I1 (https=)
FR (1) FR24C1009I2 (https=)
HR (1) HRP20201835T1 (https=)
HU (2) HUE051921T2 (https=)
IL (4) IL285976B2 (https=)
LT (2) LT3390395T (https=)
LU (1) LUC00330I2 (https=)
MA (2) MA49809A1 (https=)
MD (1) MD3390395T2 (https=)
MX (2) MX394193B (https=)
MY (2) MY202026A (https=)
NL (1) NL301262I2 (https=)
NO (1) NO2024008I1 (https=)
NZ (1) NZ743553A (https=)
PE (3) PE20181449A1 (https=)
PH (1) PH12018501268A1 (https=)
PT (1) PT3390395T (https=)
RS (1) RS60982B9 (https=)
SG (2) SG10202012498TA (https=)
SI (1) SI3390395T1 (https=)
TN (1) TN2018000213A1 (https=)
UA (2) UA122258C2 (https=)
WO (1) WO2017103611A1 (https=)
ZA (5) ZA201804137B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
WO2017103611A1 (en) 2015-12-16 2017-06-22 Redx Pharma Plc Compounds useful as kinase inhibitors
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
WO2019195810A2 (en) * 2018-04-06 2019-10-10 Praxis Biotech LLC Atf6 inhibitors and uses thereof
JP6995195B2 (ja) * 2018-05-18 2022-02-04 富士フイルム株式会社 ３－ジフルオロメチルピラゾール化合物の製造方法及び３－ジフルオロメチルピラゾール－４－カルボン酸化合物の製造方法、並びに、ピラゾリジン化合物
US12109193B2 (en) * 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021053234A1 (en) * 2019-09-19 2021-03-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여
MX2022008148A (es) 2020-01-02 2022-07-21 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de btk.
WO2021180107A1 (en) * 2020-03-12 2021-09-16 Fochon Pharmaceuticals, Ltd. Compounds useful as kinase inhibitors
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
KR102933902B1 (ko) * 2021-05-14 2026-03-05 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 공결정질 형태
CN115557933B (zh) * 2021-07-01 2024-08-16 杭州和正医药有限公司 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用
CN115611810B (zh) * 2021-07-16 2025-03-04 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
MX2024007328A (es) 2021-12-14 2024-09-30 Crossfire Oncology Holding B V Inhibidores macrociclicos de btk.
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
EP4474377A4 (en) * 2022-03-03 2025-07-30 Shenzhen Targetrx Inc Cycloalkyl or heterocyclyl substituted heteroaryl compound, and composition and use thereof
WO2023174397A1 (en) * 2022-03-18 2023-09-21 Insilico Medicine Ip Limited Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376B (zh) * 2022-12-15 2025-05-16 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途
IL322630A (en) 2023-02-22 2025-10-01 Assia Chem Ind Ltd Solid forms of pirobrutinib
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
KR20250046558A (ko) 2023-09-27 2025-04-03 임창섭 5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템
TW202532067A (zh) * 2023-12-13 2025-08-16 大陸商正大天晴藥業集團股份有限公司 含有吡唑環及雙環雜芳基的化合物
WO2025137329A1 (en) * 2023-12-22 2025-06-26 Neupharma, Inc Certain chemical entities, compositions, and methods
CN119059974B (zh) * 2024-08-12 2025-10-28 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的制备方法
CN119059973A (zh) * 2024-08-12 2024-12-03 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的合成工艺
CN120504661B (zh) * 2025-07-14 2025-11-07 复旦大学 Alkbh8小分子抑制剂及其制备方法和用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
WO2008063287A2 (en) * 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
SI2324008T1 (sl) * 2008-07-24 2012-08-31 Nerviano Medical Sciences Srl 3,4-diarilpirazoli kot protein-kinazni inhibitorji
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
CA2836449C (en) 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
EA025496B1 (ru) 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
SG11201500499TA (en) * 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
JP6178861B2 (ja) * 2012-11-02 2017-08-09 ファイザー・インク ブルトン型チロシンキナーゼ阻害剤
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
JP6615752B2 (ja) * 2013-09-30 2019-12-04 グアンジョウ・イノケア・ファーマ・テク・カンパニー・リミテッド Ｂｔｋの置換ニコチンイミド阻害剤およびそれらの調製、ならびにがん、炎症および自己免疫疾患の治療における使用
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
AU2016212230B2 (en) 2015-01-28 2019-09-19 Bayer Pharma Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018012112A2 (pt) 2015-12-16 2018-12-04 Bristol-Myers Squibb Company heteroaril-hidroxipirimidinonas como agonistas do receptor apj
KR20180095871A (ko) 2015-12-16 2018-08-28 프리오스타 피티와이 엘티디 덴드리머 및 그의 배합물
US9975882B2 (en) 2015-12-16 2018-05-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
JP6728382B2 (ja) 2015-12-16 2020-07-22 エコラブ ユーエスエイ インク 膜濾過浄化のためのペルオキシギ酸組成物
WO2017103611A1 (en) 2015-12-16 2017-06-22 Redx Pharma Plc Compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
ES3041897T3 (en) 2025-11-17
CN114716381B (zh) 2025-03-11
TN2018000213A1 (en) 2019-10-04
EP3782994B1 (en) 2025-07-16
CY1123561T1 (el) 2022-03-24
SG11201805044WA (en) 2018-07-30
CN113603645A (zh) 2021-11-05
US20210093611A1 (en) 2021-04-01
LTPA2024506I1 (https=) 2024-03-25
US20250090500A1 (en) 2025-03-20
US10918622B2 (en) 2021-02-16
US12220401B2 (en) 2025-02-11
ZA202107471B (en) 2023-03-29
CN114634447B (zh) 2024-11-15
EA035132B1 (ru) 2020-04-30
US11826351B2 (en) 2023-11-28
ES2828431T3 (es) 2021-05-26
IL259923B (en) 2020-08-31
MA55064A (fr) 2021-09-29
NL301262I2 (nl) 2024-04-24
RS60982B9 (sr) 2025-07-31
CA3008488C (en) 2023-10-10
SI3390395T1 (sl) 2020-11-30
BR112018012341A2 (pt) 2018-12-04
AU2021225161A1 (en) 2021-09-30
ZA202003176B (en) 2026-03-25
US10342780B2 (en) 2019-07-09
CN114621146A (zh) 2022-06-14
MY202026A (en) 2024-03-29
NO2024008I1 (no) 2024-02-29
KR102215792B1 (ko) 2021-02-16
CN114605327A (zh) 2022-06-10
AU2016373530A1 (en) 2018-07-05
CN114573510B (zh) 2025-02-25
MX2018007267A (es) 2018-11-09
LUC00330I2 (https=) 2026-03-04
MX394193B (es) 2025-03-21
NZ743553A (en) 2022-08-26
US20190135762A1 (en) 2019-05-09
IL285976B2 (en) 2023-10-01
US20190000806A1 (en) 2019-01-03
IL259923A (en) 2018-07-31
AU2021201811A1 (en) 2021-04-22
HRP20201835T1 (hr) 2021-01-08
CR20180367A (es) 2018-11-12
US20180362512A1 (en) 2018-12-20
CL2018001591A1 (es) 2018-09-28
CN108473481B (zh) 2022-04-19
JP2018538307A (ja) 2018-12-27
PH12018501268A1 (en) 2019-02-18
US20220062239A1 (en) 2022-03-03
CY2024003I1 (el) 2024-09-20
JP7086140B2 (ja) 2022-06-17
CN113603645B (zh) 2024-10-29
AU2021201811B2 (en) 2022-01-27
CN114716381A (zh) 2022-07-08
ZA201804137B (en) 2022-08-31
PE20181449A1 (es) 2018-09-12
US20230372298A1 (en) 2023-11-23
IL281067A (en) 2021-04-29
ZA202100544B (en) 2023-06-28
MX380907B (es) 2025-03-12
IL285976A (en) 2021-10-31
SG10202012498TA (en) 2021-01-28
JP2022120013A (ja) 2022-08-17
HK1263254A1 (en) 2020-02-21
IL276283B (en) 2021-03-25
KR20210018530A (ko) 2021-02-17
KR20180115261A (ko) 2018-10-22
PE20220502A1 (es) 2022-04-07
IL281067B (en) 2022-04-01
DK3390395T3 (da) 2020-09-28
PE20220507A1 (es) 2022-04-07
CA3008488A1 (en) 2017-06-22
FR24C1009I1 (fr) 2024-05-24
CY2024003I2 (el) 2024-09-20
EP3390395B1 (en) 2020-09-09
CN114573510A (zh) 2022-06-03
AU2021225161B2 (en) 2023-08-03
FIC20240004I1 (fi) 2024-03-01
PT3390395T (pt) 2020-11-03
EA201891268A1 (ru) 2018-11-30
CN114591242B (zh) 2025-01-07
JP6731483B2 (ja) 2020-07-29
LT3390395T (lt) 2020-11-25
IL276283A (en) 2020-09-30
EP3782994A1 (en) 2021-02-24
CN108473481A (zh) 2018-08-31
AU2016373530B2 (en) 2021-01-21
JP7419437B2 (ja) 2024-01-22
RS60982B1 (sr) 2020-11-30
US10464905B2 (en) 2019-11-05
UA127863C2 (uk) 2024-01-31
FR24C1009I2 (fr) 2025-02-07
US20200276162A1 (en) 2020-09-03
JP2020172535A (ja) 2020-10-22
CN114634447A (zh) 2022-06-17
HUS2400003I1 (hu) 2024-03-28
EP3390395A1 (en) 2018-10-24
CO2018006164A2 (es) 2018-09-20
MX2021003478A (es) 2022-07-25
CN114591242A (zh) 2022-06-07
MY200590A (en) 2024-01-04
WO2017103611A1 (en) 2017-06-22
AU2021225162A1 (en) 2021-09-30
HUE051921T2 (hu) 2021-03-29
CN113636978B (zh) 2024-10-29
AU2021225162B2 (en) 2023-08-03
ZA202107472B (en) 2023-03-29
UA122258C2 (uk) 2020-10-12
CN113636978A (zh) 2021-11-12
IL285976B1 (en) 2023-06-01
CN114605327B (zh) 2025-03-11
MD3390395T2 (ro) 2021-02-28
US10695323B2 (en) 2020-06-30
US11471441B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
WO2020160193A3 (en) Compounds and uses thereof
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
EP4506035A3 (en) Shp2 phosphatase inhibitors and methods of use thereof
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MX383213B (es) Inhibidores de tirosina-cinasas
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MX2020010805A (es) Inhibidores de bcl6.
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
PH12021550743A1 (en) Boron containing pde4 inhibitors
MX2015010983A (es) Inhibidores de tirosina-cinasa de bruton.
MA42871B1 (fr) Composés utilisés comme inhibiteurs de la tyrosine kinase de bruton (btk)
MA42175B1 (fr) Dérivés de pyrazolopyrimidine comme inhibiteurs de btk pour le traitement du cancer
MX2015010820A (es) Inhibidores de tirosina cinasa de bruton.
MA38523A1 (fr) Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma
MA45367B1 (fr) Inhibiteurs de la tyrosine kinase
EA202190690A1 (ru) Борсодержащие ингибиторы pde4
MA51297B1 (fr) Quinazolinones en tant qu'inhibiteurs de parp14